CCL2-driven inflammation increases mammary gland stromal density and cancer susceptibility in a transgenic mouse model. by Sun, Xuan et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCL2-driven inflammation increases mammary gland stromal
density and cancer susceptibility in a transgenic mouse model.
Citation for published version:
Sun, X, Glynn, DJ, Hodson, LJ, Huo, C, Britt, K, Thompson, E, Evdokiou, A, Pollard, J, Robertson, SA &
Ingman, WV 2017, 'CCL2-driven inflammation increases mammary gland stromal density and cancer
susceptibility in a transgenic mouse model.', Breast Cancer Research. https://doi.org/10.1186/s13058-016-
0796-z
Digital Object Identifier (DOI):
10.1186/s13058-016-0796-z
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Breast Cancer Research
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
Breast Cancer Research
 
CCL2-driven inflammation increases mammary gland stromal density and cancer
susceptibility in a transgenic mouse model
--Manuscript Draft--
 
Manuscript Number: BRCR-D-16-00183R1
Full Title: CCL2-driven inflammation increases mammary gland stromal density and cancer
susceptibility in a transgenic mouse model
Article Type: Research article
Funding Information: National Breast Cancer Foundation Dr Kara Britt
Prof Erik Thompson
Dr Wendy V Ingman
Hospital Research Foundation Prof Andreas Evdokiou
Dr Wendy V Ingman
Florey Medical Research Foundation Dr Xuan Sun
Wellcome Trust Prof Jeffrey W Pollard
Medical Research Council Centre for
Reproductive Health
Prof Jeffrey W Pollard
National Institutes of Health (US) Prof Jeffrey W Pollard
Victorian Breast Cancer Research
Consortium
Prof Erik Thompson
St. Vincent’s Hospital Research
Endowment Fund
Prof Erik Thompson
University of Melbourne Research Grant
Support Scheme
Prof Erik Thompson
Abstract: Background
Macrophages play diverse roles in mammary gland development and breast cancer.
CC-chemokine ligand 2 (CCL2) is an inflammatory cytokine that recruits macrophages
to sites of injury.  Although CCL2 has been detected in human and mouse mammary
epithelium, its role in regulating mammary gland development and cancer risk has not
been explored.
Methods
Transgenic mice were generated wherein CCL2 is driven by the mammary epithelial
cell-specific MMTV promoter. Estrous cycles were tracked in adult transgenic and non-
transgenic FVB mice, and mammary glands collected at the four different stages of the
cycle. Dissected mammary glands were assessed for cyclical morphological changes,
proliferation and apoptosis of epithelium, macrophage abundance and collagen
deposition, as well as mRNA encoding matrix remodelling enzymes. Another cohort of
control and transgenic mice received carcinogen DMBA and tumour development was
monitored weekly. CCL2 protein was also quantified in paired samples of high and low
mammographic density human breast tissue.
Results
Overexpression of CCL2 in the mammary epithelium resulted in an increased number
of macrophages, increased density of stroma and collagen and elevated mRNA
encoding matrix remodelling enzymes LOX and TIMP3 compared to non-transgenic
controls. Transgenic mice also exhibited increased susceptibility to development of
DMBA-induced mammary tumours. In a paired sample cohort of human breast tissue,
abundance of epithelial cell-associated CCL2 was higher in breast tissue of high
mammographic density compared to tissue of low mammographic density.
Conclusions
Constitutive expression of CCL2 by the mouse mammary epithelium induces a state of
low level chronic inflammation that increases stromal density and elevates cancer risk.
We propose that CCL2-driven inflammation contributes to the increased risk of breast
cancer observed in women with high mammographic density.
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Response to Reviewers: Dear Editor
Thank you for the opportunity to submit a revised manuscript. We confirm that this
manuscript has not been previously published and is not currently under consideration
for publication in any other journal.
Thank you for the constructive comments on this manuscript. We have addressed the
concerns raised and the manuscript is greatly improved. In particular, we have
conducted a pathological analysis of the DMBA-induced tumours, and more clearly
stated the rationale for linking CCL2 to mammographic density and use of the DMBA
tumour model, as requested. Below is a point-by-point response to each query, and the
changes made to the text are highlighted in red in the “tracked changes document”
uploaded as supplementary material.
1)Many studies have shown an important role for stromal derived CCL2 in breast
cancer. Fujimoto et al (2009, International Journal of Cancer) presented evidence for a
prognostic significance for stromal CCL2, but not epithelial CCL2 in breast cancer,
indicating tissue specific role for CCL2 in breast cancer.  While the authors appear to
be examining epithelial CCL2 as a risk factor, it is not clear what led them to only look
at epithelial CCL2 in the first place. More details in the introduction would be helpful.
The Introduction has been modified to provide a clearer rationale for investigating
epithelial specific CCL2: “Studies in mice have implicated CCL2 of epithelial tumour
cell origin, and macrophages expressing the CCL2 receptor, CCR2, as critical factors
in metastasis of breast cancer to the bone and lungs [18, 21]. These studies suggest
that epithelial cell-derived CCL2 in carcinomas might promote tumour invasion and
metastasis through increased infiltration of macrophages into tumours.” And in the
following paragraph: “Less understood is the role of CCL2 in healthy breast
development and how this may relate to the risk of cancer initiation. CCL2 protein is
detected in human breast epithelium [16, 17] and may be responsible for macrophage
recruitment under specific conditions.”
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2)The levels of CCL2 in some of the tissues in transgenic mice appear very high. Are
these levels physiologically relevant?  How do these levels relate to what is seen in
breast cancer patients or “high risk” patients ?
It is often the case with genetically modified mouse models that the concentration of
protein is altered to a level which is not necessarily physiological, whether this be a
transgenic model with high expression, or a null mutant model where the protein is
completely absent. The concentration of CCL2 has not been measured in protein
extracts of human breast to our knowledge, therefore we cannot comment on whether
the levels in the mouse model are physiological. It should be considered that breast
cancer in women develops over many years, as opposed to mouse models with
development over several months. This long latency in women means that a small
affect, such as low level inflammation, may exert a big consequence over time.
Therefore even if the level of CCL2 in the transgenic mice is not physiological, there is
still relevance to human disease, particularly in light of the increased CCL2 we have
observed in human tissue with high mammographic density. The following statement
has been added to the discussion “However, it is unknown whether the protein
concentration of CCL2 in the transgenic mice is similar or above the physiological
concentration of CCL2 which might be present in human breast.”
3)It would be very helpful to the reader if background and rationale could be provided
for the following studies in the results section:
a.DMBA induced carcinogenesis: why choose DMBA as an approach ? Why not cross
the CCL2 overexpressing mice with MMTV-PyVmT?
The advantage of the DMBA model over transgenic tumour models is described in the
methods section “Susceptibility of mice to mammary gland tumours was investigated
using the DMBA-induced mammary tumour model. This model is superior over other
mouse mammary tumour models, such as transgenic expression of polyoma middle T
oncogene targeted to the mammary gland, because tumour development does not
occur with 100% penetrance, enabling quantification and statistical analysis of cancer
susceptibility.”
b. On looking at epithelial CCL2 expression and high density tissue: Why did the
investigators choose density as a variable ? How did they make a connection to CCL2
expression ?
We did not set out to study mammographic density in these mice. The increase in
stroma was very apparent, which then raised the question of whether CCL2 might drive
mammographic density. We have further clarified this in the results section “The
increase in stroma, collagen and mammary cancer risk in Mmtv-Ccl2 mice resembled
key clinical and histological features of high mammographic density in women. To
investigate whether epithelial cell-derived CCL2 might be associated with high
mammographic density, CCL2 was quantified in paired breast tissue samples biopsied
from regions of high and low density from women undergoing prophylactic
mastectomy.”
4)Questions remain regarding the  DMBA and breast tissue studies:
a.What would be the effects of depleting macrophages from the mammary gland in
CCL2 transgenic mice ?
It would be very interesting to dissect the role of macrophages in the phenotypes we
observe in the CCL2 mice. This is a large undertaking and outside the scope of the
current study. We have addressed this point in the discussion “However, further
studies to dissect the contribution of macrophages to this phenotype are required to
establish their role in the increased mammary cancer risk observed in Mmtv-Ccl2
transgenic mice.”
b.In the results section for DMBA, what are the phenotypes for tumor invasiveness,
metastasis, tumor cell growth and proliferation?
We have conducted further pathological analysis of DMBA-induced tumours, and these
are presented in the results section and in Table 1. Veterinary pathologist Dr Lucy
Woolford has been added as a co-author of this manuscript. Similar to other recent
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
publications in Breast Cancer Research (Aupperlee et al, 2015 and Luque et al, 2016),
we find the histopathology of DMBA-induced tumours is highly variable. As different
tumour subtypes carry different mechanisms and risks of metastasis, this model is best
suited to studies on cancer susceptibility and early carcinogenesis, rather than
metastasis research.
c.In the results section for mammographic density, how does epithelial expression
compare to stromal or total tissue expression of CCL2?
CCL2 in stromal cells was detected in low abundance in these tissue sections and was
not affected by density, we have added this finding to the results. “A few cells within the
stromal compartment also stained positive for CCL2 however the abundance of these
scarce cells did not appear to be affected by density.”
d.The authors have access to prognostic factor data. Any connection between breast
tissue density, CCL2 and BRCA, family history, age etc?
The paired sample analysis of CCL2 was conducted in a sample size of 13 patients.
This sample size is too low to dissect relationships between family history, age etc.
Also, the expression in CCL2 varies considerably within the breast tissue, illustrated by
the difference observed between high and low regions of the same breast.
5)In the discussion:
a. The authors attempt to make a connection between breast cancer risk and CCL2
transgenic mice using genetic polymorphisms as a genetic example. However, the
CCL2 A/G polymorphisms are associated with stromal (monocytic) production of CCL2
and the authors are looking at epithelial CCL2 expression.
Thank you for highlighting this. We have modified the section to address this “The A/G
genotype causes increased CCL2 production in monocytes after stimulation compared
to the A/A genotype [54], and may similarly affect CCL2 expression by mammary
epithelium.”
6)Methodology :
a.It is not clear how breast density was measured and how the analysis between CCL2
expression and density was performed.
The method of density measurement and analysis of CCL2 in human breast is
described on pages 11-13 of the revised manuscript. Additional explanation and
rationale for this approach is provided at the beginning of the section titled
Quantification of CCL2 in paired human breast tissue samples, “To investigate the
relationship between mammographic density and CCL2, immunohistochemistry to
detect CCL2 was conducted on paired breast tissue samples of high (HMD) and low
mammographic density (LMD). This approach has been described previously [22, 24],
and offers excellent scope to study histological parameters associated with high
mammographic density in small sample sizes, as paired sample statistical analysis can
be applied.”
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Abstract 
Background 
Macrophages play diverse roles in mammary gland development and breast cancer. CC-chemokine 
ligand 2 (CCL2) is an inflammatory cytokine that recruits macrophages to sites of injury.  Although 
CCL2 has been detected in human and mouse mammary epithelium, its role in regulating mammary 
gland development and cancer risk has not been explored. 
Methods 
Transgenic mice were generated wherein CCL2 is driven by the mammary epithelial cell-specific 
MMTV promoter. Estrous cycles were tracked in adult transgenic and non-transgenic FVB mice, 
and mammary glands collected at the four different stages of the cycle. Dissected mammary glands 
were assessed for cyclical morphological changes, proliferation and apoptosis of epithelium, 
macrophage abundance and collagen deposition, as well as mRNA encoding matrix remodelling 
enzymes. Another cohort of control and transgenic mice received carcinogen DMBA and tumour 
development was monitored weekly. CCL2 protein was also quantified in paired samples of high 
and low mammographic density human breast tissue.  
Results 
Overexpression of CCL2 in the mammary epithelium resulted in an increased number of 
macrophages, increased density of stroma and collagen and elevated mRNA encoding matrix 
remodelling enzymes LOX and TIMP3 compared to non-transgenic controls. Transgenic mice also 
exhibited increased susceptibility to development of DMBA-induced mammary tumours. In a 
paired sample cohort of human breast tissue, abundance of epithelial cell-associated CCL2 was 
higher in breast tissue of high mammographic density compared to tissue of low mammographic 
density. 
Conclusions 
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Constitutive expression of CCL2 by the mouse mammary epithelium induces a state of low level 
chronic inflammation that increases stromal density and elevates cancer risk. We propose that 
CCL2-driven inflammation contributes to the increased risk of breast cancer observed in women 
with high mammographic density. 
 
Key Words 
Mammary gland, development, macrophage, Chemokine (C-C motif) ligand 2, mouse model, 
mammographic density 
 
Introduction  
Development and function of the mammary gland is dependent upon dynamic interactions between 
the mammary gland epithelium and surrounding stroma. Macrophages are a major component of the 
stroma, and have the capacity to direct a diverse range of biological processes necessary for mammary 
gland development, including cell proliferation, differentiation, phagocytosis, and tissue remodelling 
[1-6]. In addition to roles in healthy development, macrophages may also affect cancer susceptibility 
[7, 8]. Macrophages suppress cancer development as part of innate and adaptive anti-tumour immune 
responses, through recognition of DNA damaged cells, phagocytosis and antigen presentation to 
tumour-specific T cells [9-11]. On the other hand, macrophages can promote the proliferation and 
survival of cancer cells, facilitate tumour cell invasion, increase angiogenesis, and upregulate the 
production of pro-tumourigenic factors, and thus promote tumour progression [12-14]. In order to 
exert this wide range of effects in healthy development and cancer susceptibility in the mammary 
gland, macrophages respond to a variety of different signals in their local microenvironment, 
including cytokines emanating from other cell types, and components of the extracellular matrix.  
CC-chemokine ligand 2 (CCL2), also known as monocyte chemotactic protein 1, is a small pro-
inflammatory cytokine and is a highly potent chemoattractant for monocytes and macrophages to 
sites of tissue injury and inflammation [15, 16]. CCL2 can be highly expressed by both the tumour 
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and surrounding stromal cells in breast carcinomas [17-19]. CCL2 expression in breast carcinomas 
is highly associated with macrophage infiltration, and its expression is correlated with poor 
prognosis in breast cancer patients [18-21]. Studies in mice have implicated CCL2 of epithelial 
tumour cell origin, and macrophages expressing the CCL2 receptor, CCR2, as critical factors in 
metastasis of breast cancer to the bone and lungs [19, 22]. These studies suggest that epithelial cell-
derived CCL2 in carcinomas might promote tumour invasion and metastasis through increased 
infiltration of macrophages into tumours.   
Less understood is the role of CCL2 in healthy breast development and how this may relate to the 
risk of cancer initiation. CCL2 protein is detected in human breast epithelium [17, 18] and may be 
responsible for macrophage recruitment under specific conditions. To investigate the effect of 
CCL2 in mammary gland development and function, we developed a transgenic mouse model 
Mmtv-Ccl2, whereby CCL2 is constitutively expressed by the mammary epithelium. We find these 
mice exhibit increased macrophage recruitment to the mammary gland, perturbed mammary 
morphogenesis at the proestrus phase of the ovarian cycle and increased abundance of stroma. 
Overexpression of CCL2 also increased susceptibility to 7,12-Dimethylbenz(a)anthracene 
(DMBA)-induced mammary tumour development. These key features of the mouse model resemble 
breast tissue with high mammographic density in women, which is associated with increased stroma 
and collagen deposition [23, 24], increased immune cell abundance [25], and a 4- to 6-fold 
increased risk of breast cancer when adjusted for BMI and age [26]. A paired sample analysis of 
high and low mammographic density tissue in human breast samples showed that CCL2 protein is 
higher in tissue with high mammographic density. Combined, these findings suggest that high 
mammographic density and the associated increased cancer risk may be the result of CCL2-driven 
inflammation. 
 
Methods 
Mice 
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Animal experiments were approved by the University of Adelaide Animal Ethics Committee and 
were conducted in accordance with the Australian Code of Practice for the Care and Use of Animals 
for Scientific Purposes (7th ed., 2004). All mice were maintained in specific pathogen-free 
conditions with controlled light (12hr light, 12 hr dark cycle) and temperature at the Laboratory 
Animal Services Medical School facility. Food and water were provided ad libitum. Experiments 
utilised Mmtv-Ccl2 transgenic mice on an FVB background and non-transgenic FVB mice as 
controls. 
Estrous cycle stage was determined by analysis of vaginal smears as described previously [27]. 
Estrous cycles were tracked for at least 28 days. 
Generation of Mmtv-Ccl2 transgenic mice 
The Mmtv-Ccl2 transgenic mouse, in which the mouse mammary tumour virus 206 promoter 
(Mmtv) long terminal repeat (generously provided by Dr. William Muller, McGill University) 
constitutively drives the expression of the chemokine (C-C motif) ligand 2 (Ccl2) mRNA, was 
generated at the Albert Einstein College of Medicine (New York, USA) by Jiufeng Li. The Mmtv-
Ccl2 expression cassette was constructed by insertion of a 3.2-kb EcoRI fragment of the mouse 
genomic Ccl2 cDNA from the construct pMMJE+20 (Rutledge et al., 1995) into the EcoRI site of 
the plasmid MMTV-SV40-Bssk, which contain regulatory elements of the Mmtv promoter followed 
by the SV40 poly A site and the ampicillin-resistance gene (ampr) (Huang et al., 1981). DH5- 
cells were transformed with this construct by heat shock and selected for ampicillin resistance. 
DNA was extracted from the successfully transformed cells and the Mmtv-Ccl2 expression cassette 
was released as a PVUII fragment of 8 kb in size. This purified Mmtv-Ccl2 expression cassette was 
micro-injected into zygotes of FVB mice, which were then transferred into pseudopregnant 
recipient mothers. 
Twenty-nine offspring were generated, and three founder lines (Mmtv-Ccl2 #13, #20 and #29) were 
identified by PCR screening using a primer pair (forward: 5’-CGT CCA GAA AAC CAC AGT CA 
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-3’; reverse: 5’-CCG CTC GTC ACT TAT CCT TC-3’) covering the Mmtv promoter sequence, 
which produced a product size of 196 bp (Figure 1A). All three founders were cross-bred with 
background strain FVB mice and the genotypes of all progeny were confirmed by PCR. One female 
pup was selected from each founder line and the expression of Ccl2 mRNA from different tissues 
was measured by RT-PCR using a primer pair that spanned both endogenous genomic and 
exogenous cloned Ccl2 (forward: 5-CCC AAT GAG TAG GCT GGA GA-3’; reverse: 5’-TCT 
GGA CCC ATT CCT TCT TG-3’) and produced product sizes of 451 bp and 125 bp respectively 
(Figure 1A). The offspring from founder 29 exhibited highest expression of mRNA encoding Ccl2 
in the mammary gland and was chosen for further analysis. A homozygous Mmtv-Ccl2 transgenic 
mouse line was successfully established from founder 29 and maintained for over 5 generations on 
a FVB background.  
DMBA-induced tumour susceptibility 
Susceptibility of mice to mammary gland tumours was investigated using the DMBA-induced 
mammary tumour model. This model is superior for this purpose over other mouse mammary 
tumour models, such as transgenic expression of polyoma middle T oncogene targeted to the 
mammary mouse mammary gland, because tumour development does not occur with 100% 
penetrance, enabling quantification and statistical analysis of cancer susceptibility. Mmtv-Ccl2 and 
FVB mice received DMBA in sesame oil (1 mg/ml) weekly by oral gavage for 6 weeks from 6 
weeks of age. General health and signs of tumour development were monitored weekly. To detect 
tumours, the mammary glands were gently palpated. Mice were killed when tumours were detected 
and the tumours dissected, formalin-fixed and paraffin embedded.  
Tissue morphology and histology 
To analyse the morphology of the mammary gland, mammary glands were dissected from mice and 
spread on a glass slide. The mammary gland wholemounts were incubated in Carnoy’s fixative and 
stained in carmine alum as described previously [28]. 
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To analyse mammary gland histology, mammary glands were dissected from mice and fixed in 4% 
paraformaldehyde (PFA) (Sigma-Aldrich) for 24 h at 4oC. Paraffin-embedded tissue was cut on a 
Leica Rotary Microtome (Leica Microsystems) and placed onto SuperFrost Plus slides. Slides were 
dried overnight at 37ºC. Blocks and sections were stored at room temperature prior to staining. 
Haemotoxylin and eosin staining was performed on paraffin-embedded sections. The sections were 
dewaxed in Safsolv (Ajax, Finechem, Australia) and passed sequentially through 100%, 95%, 80% 
and 70% ethanol for rehydration. The sections were stained with haemotoxylin and counterstained 
with eosin and then mounted on coverslips.  
Masson’s Trichrome stain was used for detection of collagen fibres in paraffin-embedded mouse 
mammary gland tissue (all reagents were from Sigma-Aldrich). Slides were placed in Bouin’s fluid 
overnight at room temperature. The following day, slides were placed in Weigert’s Haematoxylin 
working solution (50% A and 50% B) for 10 minutes at room temperature and immersed in 80% 
ethanol before washing with MQ water. Slides were placed in Biebrich Scarlet solution for 2 
minutes and immersed in 5% Phosphotungstic acid for 15 minutes followed by immersing in Light 
green solution for 10 minutes. Slides were immersed in 1% glacial acetic acid for 5 minutes prior to 
dehydration, clearing and mounting.  
Immunohistochemistry 
Proliferating cells were identified by bromodeoxyuridine (BrdU) immunostaining of paraffin-
embedded mammary gland tissue. One hour prior to sacrifice, mice received an i.p. injection of 100 
µl of 10 mg/ml BrdU (Sigma). Sections were stained for BrdU incorporation into DNA using a 
BrdU In-Situ Detection Kit (BD Biosciences Pharmingen) according to the manufacturer’s 
instructions. 
Apoptotic cells were identified by terminal deoxynucleotidyl transferase dUTP nick end labelling 
(TUNEL) staining of paraffin-embedded mammary gland tissue. Sections were stained with the In-
Situ Cell Death Detection Kit (Roche) according to the manufacturer’s instructions. Only BrdU and 
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TUNEL positive cells clearly located within the ductal or alveolar epithelium were included in the 
analysis. 
Macrophage abundance was determined by F4/80 antibody staining. Five micrometer paraffin-
embedded sections mounted on glass slides were incubated with rat anti-F4/80 monoclonal antibody 
(1:100 dilution; overnight at 4ºC) (Caltag Laboratories, Burlingame, CA) followed by biotinylated 
rabbit anti-rat IgG (1:200 dilution; 40 minutes at room temperature) (Vector Laboratories) and ABC 
Elite kit (Vector Laboratories) with 3,3 diaminobenzadine (DAB) peroxidase (DAKO, Denmark). 
CCL2 was detected with polyclonal rabbit anti-mouse CCL2 (Santa Cruz Biotechnology, CA, 
USA) in 5 m paraffin-embedded sections mounted on glass slides. For antigen retrieval, slides 
were placed in 10 mM sodium citrate buffer (pH 6) and brought to 90ºC in a water bath for 20 
minutes and washed 2 times in PBS for 3 minutes each. Following CCL2 antibody incubation (1:50 
dilution; overnight at 4ºC), sections were incubated with goat anti-rabbit HRP (1:200 dilution; 
Dako) for 60 minutes at room temperature. The detection of bound antibody was performed using 
DAB according to the manufacturer’s instructions.  
Collagen-1 was detected using Alexa Fluor® 594 goat-anti rabbit IgG (Chemicon, MA, USA, 1:800 
dilution). Slides stained with secondary antibodies only or with isotype matched antibody was 
included as negative controls. All sections were mounted in fluorescent mounting medium (Dako, 
Glostrup, Denmark) with 4’,6-diamidino-2-phenylindol (DAPI) (Sigma, St Louis, USA) and were 
stored at 4ºC in the dark until image capture. 
Histology, Pathology and Immunohistochemistry Quantification 
Fluorescence images of collagen-1 and TUNEL-positive apoptotic epithelial cells were captured 
and collected using FV10i Confocal Microscope (Olympus, USA) with laser-power and 
photomultiplier settings kept constant for all experiments, and images were captured at 60 x 
magnification. Non-fluorescent stained tissue sections were captured as a digital image using a 
Nanozoomer 1.0 (Hamamatsu, Shizouka, Japan) at a zoom equivalent to 40 x objective lens. Whole 
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mount images of mammary glands were captured by MZ16 FA-Stereo microscope (Leica, The 
University of Adelaide, SA, AU).   
An assessor blinded to mouse genotype performed all quantification analysis. To determine the 
extent of ductal branching morphogenesis in whole-mounted mammary glands, the three longest 
ducts from each mammary gland were selected, the number of branch points on each duct was 
counted manually, and a mean value of 3 ducts per mammary gland were calculated and expressed 
as branch points/ mm. 
To quantify the extent of alveolar development in H&E stained sections, epithelium was 
categorized as ductal (single epithelium layer) or alveolar (clusters of epithelial structures 
containing alveolar lumens) and the numbers of ductal and alveolar epithelial structures were 
counted manually as described previously [29, 30]. The total number of alveolar buds was 
expressed as percentage of total epithelial structures (ductal plus alveolar). 
To determine the ratio of stroma and epithelium area within the mammary gland in H&E stained 
sections, five ductal epithelium and alveolar epithelium regions were randomly chosen for 
quantification. The area of stroma and epithelium was measured and represented as stroma area 
(mm2)/epithelium area (mm2). To determine the number of epithelial cells within the ductal 
epithelium, the number of haematoxylin-positive nuclei was counted.  
To determine the deposition of collagen around mammary epithelium, the amount of fibre stain 
(green) around five randomly chosen ductal epithelium and alveolar epithelium was quantified. To 
determine the number of proliferating epithelial cells and apoptotic epithelial cells, the number of 
BrdU-positive cells and TUNEL-positive cells within the epithelium was counted respectively. The 
number of F4/80 positive cells in the mammary gland was counted and only positive cells with 
visible haematoxylin stained nuclei were included. For F4/80 staining, F4/80 positive macrophages 
were distinguished from F4/80 stained eosinophils on the basis of nuclear morphology. All results 
were expressed as positive cells/mm2 or % positive cells. The mean density of positive cells within 
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the five ductal and the five alveolar stroma regions was calculated, and grouped by mouse 
genotype. 
The thickness of total collagen (indicated by red arrows) around each selected ductal epithelium 
was measured, quantified and represented as collagen thickness/m (E). The intensity of collagen I 
around each selected ductal epithelium was also measured, quantified and represented as collagen I 
density (arbitrary unit) (F). The mean fluorescence intensity (mean grey-scale value) of collagen I 
was determined and analysed using ImageJ software and a mean value of five randomly chosen 
epithelial ducts was calculated. 
Haemotoxylin and eosin stained sections of DMBA-induced mammary tumours were assessed by a 
veterinary pathologist (LW). The tumours were classified and scored for mitotic index and 
inflammation grade. Mitotic index was determined by counting the number of mitotic cells in a 10x 
field of view. Inflammation was scored on a scale of 0-5 which took into account degree of 
inflammation and degree of dispersion as either 0 (none), 1 (mild, focal), 2 (mild, multifocal), 3 
(moderate, focal), 4 (moderate, multifocal) or 5 (marked, diffuse or multifocal). 
CCL2 ELISA 
All tissues and serum were collected under sterile conditions, and the tissue was snap frozen in 
liquid nitrogen and stored at -80ºC until processing. Protein was extracted from tissues in RIPA 
buffer containing Complete Protease Inhibitor Cocktail Tablets (Roche, Basel, Switzerland). Protein 
concentration of each sample was quantified using the BCA protein assay (Thermo Scientific) 
following the manufacturer’s instructions. The limit of detection was between 20 g/ml and 2000 
g/ml.  
A CCL2 specific sandwich ELISA (eBioscience, San Diego, USA) was used to quantify mouse 
CCL2 protein in different tissues, according to the manufacturer’s instructions. Briefly, an anti-
mouse CCL2 antibody was coated onto a 96 well microtitre plate to capture CCL2 from either 
recombinant standard or assay samples. A biotinylated anti-mouse CCL2 detection antibody was 
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then used and bound antibody was quantified by the addition of streptavidin-conjugated HRP, 
followed by the addition of a chromagen substrate. After incubation for 20 min at room 
temperature, the substrate product was acidified by the addition of 50 l of 1M HCl, and 
absorbance at 450 nm (reference wavelength 570 nm) was measured using a Benckmark™ 
microplate reader (Bio-Rad Laboratories). The concentration of CCL2 within tissues and serum was 
then calculated from a standard curve (5-parameter logistic curve) using known concentrations of 
recombinant CCL2. This assay was reported by the manufacturer to have a minimum detection limit 
of 15 pg/ml, with intra- and inter-assay precision of approximately 5%. The concentration of CCL2 
in each sample is expressed relative to the protein concentration of the tissue, eg. CCL2 (pg)/protein 
(pg).  
mRNA expression 
Spleen, mammary gland, kidney, ovary and salivary gland were dissected from Mmtv-Ccl2 and 
FVB mice to quantify expression of Ccl2, Mmtv, Mmp2, Mmp9, Lox, Timp1, Timp2 and Timp3 
mRNA expression. Total RNA was extracted using Trizol (Invitrogen) and treated with DNase 
(DNA free; Ambion), then first-strand cDNA was reverse transcribed from 3 μg random hexamer-
primed RNA employing a Superscript-III Reverse Transcriptase kit. Primer pairs specific for 
published cDNA sequences were designed using Primer Express version 2 Software (Applied 
Biosystems, Foster City, CA). . The following primer pairs were used to detect specific cDNAs: 
Actb 5' GTG TGA CGT TGA CAT CCG TAA AG 3' CTC AGG AGG AGC AAT GAT CTT GAT; 
Ccl2 5' CCA GCA AGA TGA TCC CAA TGA 3' TCT CTT GAG CTT GGT GAC AAA AAC; 
Mmtv 5' CGT CCA GAA AAC CAC AGT CA 3' CCG CTC GTC ACT TAT CCT TC; Mmp2 5' 
CAA GTT CCC CGG CGA TGT C 3' TTC TGG TCA AGG TCA CCT GTC; Mmp9 5' CAG ACG 
TGG GTC GAT TCC A 3' TGT CTC GCG GCA AGT CTT C; Timp1 5' AGT CCC AGA ACC 
GCA GTG AA 3' AGT ACG CCA GGG AAC CAA GA; Timp2 5' GAG CCT GAA CCA CAG 
GTA CCA 3' GTC CAT CCA GAG GCA CTC ATC; Timp3 5’ CTT CTG CAA CTC CGA CAT 
CGT 3’ TCA GAG GCT TCC GTG TGA ATG; Lox 5’ TGC CAG TGG ATT GAT ATT ACA 
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GAT GT 3’ AGC GAA TGT CAC AGC GTA CAA. PCR amplification was performed in 
duplicate in an ABI Prism 7000 Sequence Detection System (Applied Biosystems) using SYBR 
Green PCR Master Mix (Applied Biosystems). Reaction products were analysed by dissociation 
curve profile and by 2% agarose gel (wt/vol) electrophoresis. Assay optimization and validation 
experiments were performed to define the amplification efficiency of each primer pair as described 
previously [31]. Messenger RNA abundance values were normalized independently to Actb mRNA 
expression, and data are plotted as relative expression in arbitrary units, adjusted such that the mean 
of the wild-type control group is assigned a value of 1. 
Quantification of CCL2 in paired human breast tissue samples 
To investigate the relationship between mammographic density and CCL2, immunohistochemistry 
to detect CCL2 was conducted on paired breast tissue samples of high (HMD) and low 
mammographic density (LMD). This approach has been described previously [23, 25], and offers 
excellent scope to study histological parameters associated with high mammographic density in 
small sample sizes, as paired sample statistical analysis can be applied. Briefly, ethics approval 
from the Peter MacCallum Human Research Ethics Committee (number 08/21) and St. Vincent’s 
Hospital, Victoria was obtained and the study conducted in accordance with the Australian National 
Statement on Ethical Conduct in Human Research. Breast tissue was collected from women 
undergoing prophylactic mastectomy for breast cancer prevention consented to the study through 
the Victorian Cancer Biobank (VCB 10010). These women had a confirmed BRCA1/2 carrier 
status, a past history of breast cancer in the other breast or a family history of two or more first- or 
second-degree relatives with breast cancer who were diagnosed before the age of 50 years. Resected 
breast tissue was transferred immediately on ice to the pathology department upon completion of 
mastectomy, where pathologists resected slices of breast tissue using a sterile technique. X-rays of 
those slices were taken by a breast radiographer using uniform radiological parameters and were 
assessed against a calibration ruler for selection of HMD and LMD regions. The tissue slice was 
transferred to a biosafety level 2 hood, where areas that appeared white on X-rays were selected and 
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removed using sterile blades and defined as HMD regions, and areas that appeared black were 
similarly selected, removed and classified as LMD regions. The HMD and LMD regions were 
subjected to routine formalin fixation and paraffin embedding. 
Paraffin-embedded human breast tissue sections were placed on a hotplate at 60ºC for 60 minutes 
before dewax in two 5 minutes washes in Safsolv and passed through 100%, 95%, 80% and 70% 
ethanol gradually for rehydration as described previously [23, 25]. Before sections were incubated 
with mouse anti-human CCL2 antibody (R&D systems) for 30 minutes at room temperature, 
sections were placed in Dako EnVision™ low pH antigen retrieval solution (Dako) and brought to 
90ºC in a water bath for 20 minutes followed by Envision™ wash buffer and endogenous 
peroxidase block. After primary antibody incubation, sections were incubated with Dako 
EnVision™ HRP (ready-to-use, Dako) for 30 minutes at room temperature and washed in 
Envision™ wash buffer for 5 minutes. The detection of bound antibody was performed using 
according to the manufacturer’s instructions. Tissue sections were counterstained with 
haematoxylin prior to dehydration, and cleared and mounted as described above. Slides stained with 
isotype-matched primary antibody were included as negative controls. 
Stained tissue sections were captured as a digital image using a Nanozoomer 1.0 (Hamamatsu, 
Shizouka, Japan) at a zoom equivalent to 40x objective lens. All quantification analysis was 
performed blinded. Three epithelium clusters were randomly selected from each section for 
quantification. To determine the intensity of CCL2 positive staining within the epithelium of each 
cluster, staining was quantified using the IHC profiler within Image J analysis software. The 
percentage of positive staining was determined by combining percentage of high, medium and low 
positive staining within each selected epithelium measured by the IHC profiler and a mean value of 
3 clusters per patient was calculated. 
Statistical analysis 
Data were assessed for normal distribution with a Shapiro-Wilk normality test using GraphPad 
Prism 5 (GraphPad software Inc, San Diego, USA) or SPSS Statistics Version 17.0 (IBM 
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Corporation, Armonk, NY, USA). Normally distributed data were analysed using an unpaired t-test 
with the exception of paired high and low mammographic density samples, which were analysed by 
paired t-test. Not normally distributed data were analysed using a Mann-Whitney U test. Data are 
presented as the mean ± SEM (standard error of mean). Kaplan-Meier survival curves were 
generated using SPSS Statistics Version 17.0 to analyse survival function and LogRank test was 
used to compare different Kaplan–Meier curves between groups. Tumour incidence was analysed 
by Chi-squared test. The difference between control and transgenic groups was considered 
statistically significant if p < 0.05 and is indicated on the figures by an asterisk (*). 
 
Results 
Elevated expression of Ccl2 mRNA and protein in Mmtv-Ccl2 mice 
To determine whether CCL2 abundance was elevated in transgenic mice, mRNA encoding the 
MMTV promoter and CCL2, as well as CCL2 protein, were investigated in offspring from mouse 
founder line #29. CCL2 protein was clearly detectable in the lumen of the mammary gland of 
Mmtv-Ccl2 mice by immunohistochemistry, and was substantially elevated compared to the very 
low abundance in non-transgenic control mice (Figure 1B and C). No positive staining was 
observed in the mammary epithelium stained with isotype-matched negative control antibody (not 
shown). Messenger RNA encoding MMTV was virtually undetectable in the spleens, kidneys, 
ovaries and livers of all mice, and in the mammary gland and salivary gland of non-transgenic 
control mice (Figure 1D). However, abundance of mRNA encoding MMTV was detectable in the 
mammary gland and salivary gland of Mmtv-Ccl2 mice and was 15- and 125-fold higher 
respectively compared to control mice. Consistent with previous studies using CCL2 expression 
cassettes driven by different promoters [32-34], elevated abundance of CCL2 was observed not only 
in the tissue of interest, but also in other tissues and in the blood of Mmtv-Ccl2 mice. Abundance of 
Ccl2 mRNA was significantly elevated in the spleen, kidney, salivary gland, mammary gland and 
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liver of Mmtv-Ccl2 mice compared to control mice (Figure 1E). The abundance of CCL2 protein 
was also elevated in the spleen, liver, salivary gland, and mammary gland and in the serum of 
Mmtv-Ccl2 mice compared to control mice (Figure 1F).  
CCL2 overexpression increases recruitment of macrophages to the mammary gland 
To investigate the effect of epithelial cell-derived CCL2 on the number of macrophages in the 
mammary gland, F4/80 immunohistochemistry was performed. F4/80-positive macrophages were 
observed in close proximity to ductal and alveolar epithelium in the mammary glands from both 
control (Figure 2A and C respectively) and Mmtv-Ccl2 mice (Figure 2B and D respectively). No 
positive staining was observed in the mammary glands stained with isotype-matched irrelevant 
antibody (not shown). The density of macrophages in regions surrounding both ductal and alveolar 
epithelium was increased in Mmtv-Ccl2 mice compared with control (Figure 2E). 
CCL2 overexpression perturbs mammary gland morphogenesis during the estrous cycle  
CCL2 overexpression did not affect estrous cyclicity. Estrous cycle length was (mean±SEM) 
5.4±0.1 days for both Mmtv-Ccl2 and control mice (n=29 per genotype). There was no significant 
difference in the percent of time spent in each of the 4 stages of the estrous cycle between the two 
groups. To assess the impact of CCL2 overexpression on mammary gland development across the 
estrous cycle, adult mammary glands from control and Mmtv-Ccl2 transgenic mice were dissected 
at the different stages of the cycle and compared morphologically and histologically (Figure 3). 
Despite normal secondary branching and alveolar architecture during the development phase of the 
cycle (metestrus and diestrus) in transgenic mice, Mmtv-Ccl2 mice exhibited increased density of 
branch points (Figure 3K) and an increase in the tissue area comprised by alveolar epithelium 
(Figure 3L) at the proestrus phase of the cycle, suggesting a perturbation in the cyclic regression of 
the mammary gland. Thus, mammary gland function at the proestrus phase of the cycle was 
investigated in further experiments. 
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To investigate the effect of CCL2 on epithelial cell turnover at the proestrus phase of the cycle, 
mammary glands from Mmtv-Ccl2 and control mice were stained for BrdU, indicative of cell 
proliferation, and TUNEL, indicative of cell death. BrdU-positive cells were observed in both 
ductal and alveolar epithelium of mammary glands from control (Figure 4A and C; respectively) 
and Mmtv-Ccl2 (Figure 4B and D; respectively) mice. There was no significant difference in the 
density of proliferating ductal or alveolar epithelial cells in Mmtv-Ccl2 compared to control mice 
(Figure 4I). TUNEL-positive cells were observed in both ductal and alveolar epithelium of 
mammary glands from control (Figure 4E and G; respectively) and Mmtv-Ccl2 (Figure 4F and H; 
respectively) mice. There was no significant difference in the density of TUNEL-positive ductal or 
alveolar epithelial cells in Mmtv-Ccl2 compared to control mice (Figure 4J). 
Upon further examination of H&E stained thin sections, an increased thickness of stroma 
surrounding epithelial ducts was evident in the mammary glands of transgenic mice. To investigate 
this, the ratio of stroma to epithelium was quantified in H&E stained sections from control and 
Mmtv-Ccl2 mice at proestrus (Figure 5A and B respectively). There was a 2-fold increase in the 
area of stroma relative to epithelium in Mmtv-Ccl2 mice (Figure 5C). The increase in stroma in 
CCL2 overexpressing mice was further investigated by analysing the extracellular matrix. The 
thickness of collagen, assessed by Masson’s trichrome stain, in control and Mmtv-Ccl2 (Figure 5D 
and E respectively) mice was increased (Figure 5F) however the abundance of monomeric collagen 
1 detected by collagen I antibody staining was comparable in Mmtv-Ccl2 mice (Figure 5G-I). 
Quantitative RT-PCR was used to analyse the expression of mRNAs encoding enzymes that are 
involved in collagen remodelling. The abundance of both lysyl oxidase (Lox) and tissue inhibitor of 
metalloproteinase 3 (Timp3) mRNA were increased in mammary glands of Mmtv-Ccl2 mice 
compared to control mice, while matrix metalloproteinase 2 (Mmp2), Mmp9, Timp1 and Timp2 
mRNA were not significantly altered (Figure 5J). Combined, these results suggest that CCL2 
overexpression causes increased abundance of stroma surrounding epithelium through perturbation 
of remodelling of the extracellular matrix.  
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CCL2 overexpression increases susceptibility to DMBA-induced mammary gland cancer  
To investigate the effect of CCL2 overexpression on mammary gland cancer susceptibility, control 
and Mmtv-Ccl2 mice were challenged with the chemical carcinogen DMBA. Tumour free survival 
was analysed on a Kaplan-Meier plot (Figure 6). The incidence of mammary tumours was higher in 
Mmtv-Ccl2 mice, with 14 of 18 mice (78%) developing a mammary gland tumour compared to 8 of 
18 (44%) control mice developing a mammary gland tumour (p=0.04). There was also a significant 
decrease in mammary tumour free survival in Mmtv-Ccl2 mice compared to control mice 
(p=0.025); mean latency was (mean±SD) 12.7±1.0 weeks in Mmtv-Ccl2 mice, and 16.7±1.4 weeks 
in control mice.  
Analysis of a subset of the tumours revealed the majority were adenosquamous carcinomas, with 
early mammary intraepithelial neoplasia and other carcinoma types present (Table 1). The mitotic 
index and inflammation score varied widely between tumours, and there was no significant 
difference in these parameters between control and Mmtv-Ccl2 mice.  
Epithelial cell CCL2 is increased in breast tissue of high mammographic density in women 
The increase in stroma, collagen and mammary cancer risk in Mmtv-Ccl2 mice resembled key 
clinical and histological features of high mammographic density in women. To investigate whether 
epithelial cell-derived CCL2 might be associated with high mammographic density, CCL2 was 
quantified in paired breast tissue samples biopsied from regions of high and low density from 
women undergoing prophylactic mastectomy. CCL2 staining was observed in the epithelium of 
human breast tissue of low and high mammographic density while no staining was present in 
isotype-matched antibody control sections (Figure 7). A few cells within the stromal compartment 
also stained positive for CCL2 however the abundance of these scarce cells did not appear to be 
affected by density. Abundance of CCL2 in epithelial cells, as measured by intensity of CCL2 
staining, was increased in tissue with high mammographic density compared to the paired low 
mammographic density tissue from the sample patient (p=0.03).  
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 Discussion  
This study investigated the significance of CCL2 in regulating macrophage recruitment, healthy 
mammary gland development, and the risk of cancer. Overexpression of CCL2 by the mammary 
gland epithelium was achieved through generation of a transgenic mouse model wherein Ccl2 
mRNA expression was under the control of the mammary epithelial cell-specific promoter MMTV. 
Consistent with the known role of CCL2 as a macrophage chemoattractant [33, 35, 36], constitutive 
expression of epithelial cell-specific CCL2 resulted in increased abundance of stromal macrophages 
in the mammary gland. Therefore, this mouse model enabled the examination of the effect of CCL2 
on macrophage infiltration, collagen remodelling, cyclic mammary gland regression and DMBA-
induced cancer risk. 
CCL2 overexpression perturbs mammary gland regression and collagen remodelling 
In cycling non-pregnant mice, the mammary epithelium undergoes ductal development and 
regression over the course of each ovarian cycle under the influence of ovarian hormones [29]. For 
the mammary gland to undergo these dynamic developmental processes, tight regulation of signals 
within the cytokine microenvironment that affect the balance between proliferation, differentiation, 
and apoptosis, as well as tissue breakdown and repair is required [8, 37]. Increased ductal branch 
points and abundance of alveolar buds observed in mice overexpressing CCL2 at the proestrus 
phase of the cycle suggests that despite normal estrous cyclicity, mammary gland regression was 
perturbed. However, at estrus, the mammary epithelium exhibited a normal basic ductal structure, 
implying that regression is delayed rather than completely inhibited.  
Little is known of the role of CCL2 in mammary gland development and function, however some 
studies suggest that it may be involved in mediating inflammation associated with the early 
response to tissue injury and post-weaning involution. Elevated expression of CCL2 is observed 
during the first stage of mammary gland involution, where it is believed to be involved in early 
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recruitment of macrophages, and decreases during the later stage of involution when tissue 
remodelling peaks [38]. Lipopolysaccharide administered to the lactating mammary gland increases 
abundance of CCL2, which precedes macrophage recruitment and partial mammary gland 
involution [39]. These instances of acute elevation in CCL2 may form part of the immune signalling 
fingerprint that promotes an inflammatory response, however later suppression of CCL2 may be 
required for appropriate tissue remodelling.  
Mammary gland regression during the ovarian cycle involves a series of processes, including 
apoptosis of the mammary epithelial cells, clearance of dying epithelial cells by phagocytosis and 
remodelling of mammary extracellular matrix [7, 40]. Epithelial cell proliferation and apoptosis was 
unaffected by constitutive expression of the Ccl2 transgene by mammary epithelium, which 
suggests that CCL2 might not affect epithelial cell turnover in the adult cycling mammary gland. 
However, the stromal area around ductal mammary epithelium was significantly larger in the 
presence of epithelial cell-derived CCL2, and therefore CCL2 might be involved in regulation of 
the process of stroma breakdown and repair necessary for cyclic remodelling.  
Mammary gland stroma is composed of extracellular matrix proteins, and a wide variety of cells, 
including fibroblasts and leukocytes such as macrophages and eosinophils. Collagen is a prominent 
component of extracellular matrix in the mammary gland stroma that contributes significantly in 
supporting tissue integrity and elasticity; furthermore; the deposition and remodelling of collagen 
has been found to be highly associated with normal mammary gland development and 
tumourigenesis [41-43]. Increased Timp3 mRNA expression was observed in CCL2 overexpressing 
mice, indicating CCL2 may enhance the inhibitory effect of TIMPs on MMP-mediated collagen 
degradation, resulting in elevated collagen deposition. Moreover, high expression of epithelial cell-
derived CCL2 also causes increased expression of lysyl oxidase mRNA (Lox), a collagen 
crosslinking enzyme involved in cross-linking elastin and collagen in extracellular matrix and hence 
enhancing tissue integrity [43]. This could also contribute to the increased collagen deposition 
around mammary epithelium in the presence of abundant CCL2, as increased LOX expression 
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could lead to increase mammary gland stromal stiffness and collagen cross-linking, which could 
further inhibit MMP-mediated collagen degradation. Although mRNA for collagens and other 
collagen biosynthesis proteins were not assessed, however their coordinated upregulation is 
feasible. 
CCL2-driven inflammation is known to promote fibrosis and collagen deposition in a number of 
disease states, including human pulmonary fibrosis [44], bleomycin-induced pulmonary fibrosis in 
rats and mice [45, 46], and interstitial renal fibrosis in mice [47]. Macrophages are an essential 
mediator of inflammation-associated fibrosis, and have been shown to promote collagen synthesis 
in vitro [48-50]. In the mammary gland, macrophages promote collagen fibrillogensis as a critical 
part of healthy pubertal development [2]. Therefore, increased abundance of mammary gland 
macrophages, stroma and collagen in CCL2 overexpressing mice is consistent with the known role 
of CCL2 in driving inflammation and collagen deposition. 
These findings suggest that CCL2-driven inflammation increases collagen deposition and inhibits 
collagen remodelling around the mammary epithelium. Through promotion of macrophage 
recruitment and the activities of TIMP3 and LOX, high CCL2 expression would be expected to 
cause imbalance in the turnover of collagen, which in turn could impair mammary gland regression 
during the proestrus phase of the ovarian cycle.   
CCL2-driven breast cancer risk 
It is well established that chronic inflammation increases cancer risk through oncogenic mutations, 
genome instability, early tumour promotion, and enhanced angiogenesis [13, 14]. Chronic 
inflammation leads to collagen deposition and fibrosis associated with increased LOX expression 
[51] and increased stromal collagen deposition has also long been recognised as a major 
contributing factor to the increased mammographic density that increases risk of breast cancer [23, 
25, 52, 53]. This study suggests that expression of epithelial cell-specific CCL2 by mammary 
epithelium increased mammary cancer susceptibility in mice through inducing a low level of 
chronic inflammation in the mammary gland, characterised by increased macrophage infiltration 
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and fibrosis associated with perturbed collagen deposition and remodelling. However, further 
studies to dissect the contribution of macrophages to this phenotype are required to establish their 
role in the increased mammary cancer risk observed in Mmtv-Ccl2 transgenic mice. 
Population studies support the notion that increased CCL2 expression increases breast cancer risk 
and cancer progression. The risk of developing metastasis is significantly increased in breast cancer 
patients carrying the CCL2-2518 A/G promoter polymorphism compared to A/A homozygotes [54]. 
The A/G genotype causes increased CCL2 production in monocytes after stimulation compared to 
the A/A genotype [55], and may similarly affect CCL2 expression by mammary epithelium. 
However, it is unknown whether the protein concentration of CCL2 in the transgenic mice is similar 
or above the physiological concentration of CCL2 which might be present in human breast. In 
addition, altered responsiveness to CCL2 through polymorphism in the receptor CCR2 also affects 
breast cancer susceptibility. The CCR2-64I polymorphism, which slightly impairs capacity to 
transduce CCL2 signals, is underrepresented in breast cancer patients [17, 56], and this might 
provide protection from tumour formation through reduced recruitment of tumour-promoting 
macrophages. 
High mammographic density is associated with a 4- to 6-fold increased breast cancer risk in the 
highest versus lowest quartiles, and after correction for BMI and age [26]. Although the biological 
mechanisms that regulate mammographic density are poorly understood, high mammographic 
density is associated with increased stroma, collagen deposition and TIMP3 protein compared to 
tissue of low mammographic density [57-59]. These biological characteristics are strikingly similar 
to the mammary glands of Mmtv-Ccl2 transgenic mice, where overexpression of CCL2 caused 
increased abundance of stroma, collagen thickness, mRNA encoding TIMP3 and elevated risk of 
DMBA-induced mammary cancer. An inflammatory basis for high mammographic density is 
suggested by studies in paired samples of high and low mammographic density tissue. Tissue with 
high mammographic density exhibits elevated inflammatory COX2, increased number of vimentin 
positive immune cells within the epithelium, and reduced abundance of CD206-positive 
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“alternatively activated” macrophages compared to paired breast tissue of low mammographic 
density [25, 60, 61], as well as the increase in CCL2 reported here. Based on these observations, we 
propose that CCL2-driven inflammation might play a role in increasing mammographic density and 
breast cancer risk.  
The potential role of inflammation in driving high mammographic density suggests that use of non-
steroidal anti-inflammatory drugs (NSAID), which are already known to reduce breast cancer risk 
[62, 63], could be effective in reducing mammographic density. In a mouse model of high 
mammographic density, Celecoxib, a selective NSAID that specifically inhibits COX2, reduced 
collagen deposition in the mammary gland, and reduced tumour development and metastasis [64]. 
Although there appears to be no association between NSAID use and mammographic density [65], 
a study of nearly 30,000 postmenopasual women found that NSAID use reduced the risk of 
increasing mammographic density over a 9 to 28 month period [66]. Further studies investigating 
the potential for NSAID to reduce breast cancer risk associated with high mammographic density 
are required.  
Conclusion 
Constitutive expression of CCL2 by the mouse mammary epithelium induces a state of low level 
chronic inflammation that perturbs collagen remodelling and elevates cancer risk. We propose that 
CCL2-driven inflammation contributes to the increased risk of breast cancer observed in women 
with high mammographic density. Future studies will examine how CCL2 is regulated in the 
mammary gland, and the biological function of CCL2 in increasing mammographic density in 
women. Understanding the underlying cellular mechanisms of how inflammation affects breast 
function will shed light on cancer susceptibility and may uncover new opportunities to 
therapeutically reduce breast cancer risk.  
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Ampr ampicillin-resistance gene, BMI body mass index, BrdU bromodeoxyuridine, CCL2 CC-
chemokine ligand 2, CCR2 CCL2 receptor, DAB 3,3 diaminobenzadine, DAPI 4’,6-diamidino-2-
phenylindol, DMBA 7,12-Dimethylbenz(a)anthracene, HMD high mammographic density, LMD 
low mammographic density, LOX lysyl oxidase, MMP matrix metalloproteinase, MMTV Mouse 
mammary tumour virus 206 promoter, PFA paraformaldehyde, SEM standard error of the mean, 
TIMP tissue inhibitor of matrix metalloproteinases, TUNEL terminal deoxynucleotidyl transferase 
dUTP nick end labelling 
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Legend 
Figure 1. Generation of Mmtv-Ccl2 transgenic mice. The Mmtv-Ccl2 expression cassette was 
detected in three of twenty nine mice by PCR screening and the expression of both endogenous 
genomic and cloned Ccl2 mRNA in different tissues was measured by RT-PCR with product sizes 
of 451 bp and 125 bp, respectively (A). CCL2 protein detected by immunohistochemistry in the 
mammary gland from female offspring from founder mouse #29 (B) compared to non-transgenic 
control (C). RNA encoding MMTV (D) and CCL2 (E), and CCL2 protein (F) were quantified in 
spleen (Sp), kidney (Kid), ovary (Ov), liver (Liv), salivary gland (SG) and mammary gland (MG) 
from Mmtv-Ccl2 and non-transgenic control mice. Abundance of mRNA was normalised to Actb 
expression, and is given in arbitrary units where the average of the non-transgenic mammary gland 
control is 1. n=5 per group. Data are presented as mean + SEM with statistical analysis conducted 
using an unpaired t test, *p < 0.05.  
Figure 2. The effect of CCL2 overexpression on macrophage abundance and location within and 
around mammary epithelium. Paraffin sections of mammary gland tissue from control and Mmtv-
Ccl2 were stained with anti-macrophage-specific F4/80 antibody to detect macrophages in the 
stroma surrounding ductal (A, B) and alveolar epithelium (C, D) of mammary glands from adult 
control and Mmtv-Ccl2 mice. Macrophages are indicated by red arrows. The number of F4/80-
positive macrophages was quantified and represented as F4/80-positive macrophages/mm2 (E). n=6 
per group. Data are presented as mean + SEM with statistical analysis conducted using an unpaired 
t test, *p < 0.05. 
Figure 3. The effect of CCL2 overexpression on mammary gland morphogenesis during ovarian 
cycle. Mammary glands from control and Mmtv-Ccl2 mice were wholemounted and stained with 
carmine alum at estrus (A, E), metestrus (B, F), diestrus (C, G) and proestrus (D, H) respectively. 
The number of branch points/mm was calculated (K). Sections of paraffin embedded mammary 
glands from control and Mmtv-Ccl2 mice at the 4 stages of the cycle were H&E stained (I, J 
respectively, only proestrus stage shown) and alveolar epithelium quantified (L).  n=6-9 per group. 
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Data are presented as mean + SEM with statistical analysis conducted using an unpaired t test, *p < 
0.05. 
Figure 4. The effect of CCL2 overexpression on mammary epithelial cell proliferation and cell 
death. Paraffin-embedded sections of mammary gland tissue from control and Mmtv-Ccl2 mice at 
proestrus were stained with anti-BrdU antibody to detect proliferating ductal (A and B) and alveolar 
(C and D) epithelial cells. The number of BrdU-positive cells (brown-stained cells) within ductal 
and alveolar epithelium was calculated and expressed as BrdU-positive cells/mm2 (I). Paraffin-
embedded sections of mammary gland tissue from control and Mmtv-Ccl2 mice at proestrus were 
stained with TUNEL to detect dying ductal (E and F) and alveolar (G and H) epithelial cells. The 
percent of TUNEL-positive cells (green-stained cells) within ductal and alveolar epithelium was 
calculated (J). n=6 per group. Data are presented as mean + SEM with statistical analysis conducted 
using an unpaired t test, *p < 0.05. 
Figure 5. The effect of CCL2 overexpression on abundance of stroma and collagen. Sections of 
mammary gland tissue from control (A, D, F) and Mmtv-Ccl2 (B, E, H) mice at proestrus were 
stained with H&E (A, B), Masson’s trichrome (C, D) and collagen I antibody (G, H) and quantified 
(C, F, I). n=6 per group. Data are presented as mean + SEM with statistical analysis conducted 
using an unpaired t test. * indicates statistical significance from control. *p < 0.05. Mammary gland 
from both groups of mice (n=8) were dissected and frozen in liquid nitrogen. Messenger RNAs of 
collagen remodelling enzymes including Lox, Mmp2, Mmp9, Timp1, Timp2 and Timp3 was 
extracted and measured by RT-PCR. Amount of mRNA was normalised to Actb expression, and is 
given in arbitrary units where the average of the control is 1. Data are presented as mean + SEM 
with statistical analysis conducted using an unpaired t test. * indicates statistical significance from 
control. *p < 0.05.  
Figure 6. The effect of CCL2 overexpression on mammary gland cancer susceptibility in mice. 
Kaplan-Meier survival plot showing the percentage of tumour-free mice following DMBA 
treatment in weeks for control and Mmtv-Ccl2 mice. n=18 per group. In Mmtv-Ccl2 mice, the 
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incidence of mammary tumours was increased (p=0.04 Chi squared) and mammary tumour free 
survival was reduced (p=0.025 Log rank) compared to control mice. 
Figure 7. CCL2 in paired samples of high and low mammographic density. CCL2 immunostaining 
of human breast tissue of low (A) and high (B) mammographic density and isotype-matched 
negative control (C). Intensity of staining within the epithelium was quantified and data are 
presented as percent change in abundance of CCL2 in high density tissue compared to low density 
tissue for each paired sample, a horizontal bar indicates the mean (D), analysed by paired sample t-
test (n=13).  
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Genotype Latency (wks) Histopathology 
Mitotic 
index 
Inflammation 
Control 13 Spindeloid carcinoma 0 2 
 10 Adenosqaumous carcinoma  3 5 
 14 Adenosqaumous carcinoma  2 2 
 16 Early MIN 0 0 
 10 Adenosquamous carcinoma N/A 4 
 12 Adenosquamous carcinoma 1 4 
 11 Carcinosarcoma  0 2 
 10 Early MIN 0 1 
Mmtv-Ccl2 10 Acinar 0 0 
 11 Adenosquamous carcinoma N/A 2 
 10 Adenosquamous carcinoma 2 5 
 19 Early MIN 0 0 
 10 Adenosqaumous carcinoma  0 2 
 13 Glandular carcinoma 0 2 
 13 Cribiform carcinoma 1 4 
 8 Adenosquamous carcinoma 1 5 
 19 Early MIN 0 0 
Table 1. Characteristics of DMBA-induced tumours from control and Mmtv-Ccl2 mice. Latency in 
weeks after final DMBA administration. Mammary intraepithelial neoplasia (MIN). Mitotic index 
was determined by counting the number of mitotic cells in a 10x field of view. Inflammation was 
scored as 0 (none), 1 (mild, focal), 2 (mild, multifocal), 3 (moderate, focal), 4 (moderate, 
multifocal) or 5 (marked, diffuse or multifocal). N/A not assessed. 
Table Click here to download Table table 1.docx 
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